Weiqiang Zhao MD, PhD


Weiqiang Zhao MD, PhD
Assoc Professor - ClinicalCollege of Medicinezhao.186@osu.edu
1000 Polaris 2001 Polaris Parkway Columbus Ohio 43240
Phone:614-293-4210Fax: 614-293-7013
  • Molecular Biology and Cancer Genetics

Research Description

Dr. Zhao's research interest include investigating and validating biomarkers in molecular pathogenesis, diagnosis, and target intervention in cancer and leukemia. One of his projects is to study the role of isoform 6 of IKZF1 gene in leukemia or lymphoma progression which has been shown to be leukemogenic in Philadelphia chromosome positive ALL. In addition, his laboratory is studying the novel role of CYP2E1 in differentiation of megakaryopoiesis. In cancers, the lab is interested in cell cycle dysregulation by activating mutations of EGFR, KRAS, and EML4-ALK genes in lung cancer.

Current Publications

  • Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JCValidation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.Blood 124 42-8 7/3/2014
  • Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KAComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.Cancer 120 1677-85 6/1/2014
  • Han C, Zhao R, Liu X, Srivastava A, Gong L, Mao H, Qu M, Zhao W, Yu J, Wang QEDDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer.Mol Cancer Res 12 784-94 5/1/2014
  • Chen W, Brodsky SV, Zhao W, Otterson GA, Villalona-Calero M, Satoskar AA, Hasan A, Pelletier R, Ivanov I, Ross P, Nadasdy T, Shilo KY-chromosome status identification suggests a recipient origin of posttransplant non-small cell lung carcinomas: chromogenic in situ hybridization analysis.Hum Pathol 45 1065-70 5/1/2014
  • Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski MA, Villalona-Calero MAErlotinib in African Americans With Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses.Clin Pharmacol Ther in press 4/29/2014
  • Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JCProlonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.Blood 123 1810-7 3/20/2014
  • Zhao R, Han C, Eisenhauer E, Kroger J, Zhao W, Yu J, Selvendiran K, Liu X, Wani AA, Wang QEDNA damage-binding complex recruits HDAC1 to repress Bcl-2 transcription in human ovarian cancer cells.Mol Cancer Res 12 370-80 3/1/2014
  • Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JCA phase I trial of flavopiridol in relapsed multiple myeloma.Cancer Chemother Pharmacol 73 249-57 2/1/2014
  • O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JCIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.Lancet Oncol 15 48-58 1/1/2014
  • Park MM, Ebel JJ, Zhao W, Zynger DLER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.Breast J 20 37-45 1/1/2014
  • Jones JA, Ruppert AS, Zhao W, Lin TS, Rai K, Peterson B, Larson RA, Marcucci G, Heerema NA, Byrd JCPatients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.Leuk Lymphoma 54 2654-9 12/1/2013
  • Kamangar E, Zhao WHemophagocytosis in a patient with persistent chronic lymphocytic leukemia.Blood 122 2149 9/26/2013
  • Yearsley MM, Frankel WL, Zhou XP, Zhao W, Huang CCLeft-sided sessile serrated polyps/adenomas--reply.Hum Pathol 44 1960-1 9/1/2013
  • Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien STargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.N Engl J Med 369 32-42 7/4/2013
  • Huang CC, Frankel WL, Doukides T, Zhou XP, Zhao W, Yearsley MMProlapse-related changes are a confounding factor in misdiagnosis of sessile serrated adenomas in the rectum.Hum Pathol 44 480-6 4/1/2013
  • Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161 156-64 3/1/2013
  • Hertlein E, Beckwith KA, Lozanski G, Chen TL, Towns WH, Johnson AJ, Lehman A, Ruppert AS, Bolon B, Andritsos L, Lozanski A, Rassenti L, Zhao W, Jarvinen TM, Senter L, Croce CM, Symer DE, de la Chapelle A, Heerema NA, Byrd JCCharacterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.PLoS One 8 e76607 1/1/2013
  • Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W, Otterson GACellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors.Diagn Pathol 8 201 1/1/2013
  • Lozanski G, Pennell M, Shana'ah A, Zhao W, Gewirtz A, Racke F, Hsi E, Simpson S, Mosse C, Alam S, Swierczynski S, Hasserjian RP, Gurcan MNInter-reader variability in follicular lymphoma grading: Conventional and digital reading.J Pathol Inform 4 30 1/1/2013
  • Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, Zhao W, Bekaii-Saab TInfluence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.Cancer 118 6243-52 12/15/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu